ClinicalTrials.gg
RecruitingNCT05987449Updated Nov 5, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

A Phase 1/2 interventional study of NXT007 in Hemophilia A, sponsored by Hoffmann-La Roche. Recruiting at 14 sites in 6 countries. Open to male participants aged 2 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
2 Years to 59 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Hemophilia A by Hoffmann-La Roche — 5 open to participants now, 8 under way, 4 of them phase 3. Hemophilia A · Hoffmann-La Roche.

Planned enrollment
10th of 20
60 · median 58
Started
2023
the only one that year
Phase 1/2
4 of 25
2 open now
Registered
20th of 25
by date

Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 1/2, and was the 20th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

5 of the 25 studies in Hemophilia A by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 2 Years to 59 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hemophilia A by Hoffmann-La Roche, or all of them as a file.
02

Study summary

WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts:

  • Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors.
  • Part 2 is a multiple-dose study in pediatric male participants with severe or moderate hemophilia A with or without FVIII inhibitors.

The overall aim of the study is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of NXT007.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
2 Years to 59 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of severe (Factor VIII coagulant activity [FVIII:C] \<1 IU/dL) or moderate (FVIII:C ≥1 IU/dL and ≤5 IU/dL) congenital hemophilia A with or without inhibitors against FVIII
  • Participants with FVIII inhibitors: participants using recombinant activated factor VII (rFVIIa) or willing to switch to rFVIIa as primary bypassing agent for the treatment of breakthrough bleeds, trauma, or procedures
  • Historic local FVIII inhibitor test results being available during screening to confirm any previous inhibitor history and current status
  • Participants who previously successfully completed immune tolerance induction (ITI) must have done so at least 5 years before screening and must have no evidence of inhibitor recurrence (permanent or temporary) since. FVIII tolerance defined as \<0.6 Bethesda unit (BU)/mL (\<1.0 BU/mL only for laboratories with an historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL) and in vivo recovery >66%
  • Documentation of number and type of bleeding episodes in the last 24 weeks prior to enrollment
  • Adequate hematologic function, defined as count ≥100,000 cells/μL and ≥11 g/dL at the time of screening
  • Adequate hepatic function defined as total ≤1.5× age-adapted (ULN) (excluding Gilbert syndrome) and both (AST) and alanine aminotransferase (ALT) ≤3× age-adapted ULN at the time of screening, and no clinical signs or known laboratory/radiographic evidence consistent with cirrhosis. For patients with Gilbert syndrome, bilirubin should be \<4 mg/dL or 68.4 umol/L at the time of screening.
  • For Part 1 only: Adequate renal function, defined as serum creatinine ≤2.5× age-adapted ULN and calculated ≥30 mL/min by Cockroft-Gault formula
  • For Part 2 only: Adequate renal function, defined as serum creatinine ≤1.5× age-adapted ULN. When the serum creatinine is ≥1.5× ULN, creatinine clearance by Bedside Schwartz formula must be >70 mL/min/1.73m\^2.
  • Willingness and ability to comply with schedules visits, treatment plans, laboratory tests, and other study procedures

Exclusion criteria

Exclusion Criteria:

  • Inherited or acquired bleeding disorders other than congenital hemophilia A
  • Ongoing or planned ITI therapy
  • Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
  • At high risk for thrombotic microangiopathy (TMA), including past personal or family history of TMA, in the investigator's judgment
  • For Part 1 only: Personal history of ischemic heart disease, cerebrovascular disease, or diabetes mellitus
  • For Part 1 only: Strong family history of ischemic heart disease or cerebrovascular disease (i.e., first degree relatives such as parents, full siblings, or children): male relatives diagnosed under the age of 55 years and females under the age of 65 years
  • For Part 1 only: Previous or concomitant or leukemia
  • Other conditions (e.g., conditions such as Systemic Lupus erythematosus and other systemic inflammatory disorders) that may currently increase the risk of bleeding or thrombosis
  • History of allergies
  • Receipt of any of the following:

    i) An drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration or normalization of targeted parameters (e.g., anti-thrombin), whichever is longer; ii) A non-hemophilia-related investigational drug within last 30 days or 5 half-lives, whichever is shorter; iii) Any other investigational drug currently being administered or planned to be administered; iv) Prior gene therapy or gene therapy planned to be administered; v) Use of systemic immunomodulators (e.g., interferon or rituximab) at enrollment or planned use during the study, with the exception of anti-retroviral therapy to treat .

  • Protein C activity, protein S free antigen, or anti-thrombin III activity levels below the lower limit of the reference range at screening
  • Known HIV infection with \<200 cells/μL
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy and to chimeric or humanized antibodies or fusion proteins
  • Known to Chinese hamster ovary cell products or to content
  • History or presence of an abnormal that is deemed clinically significant, (e.g., complete left bundle branch block, second- or third -degree atrioventricular heart block), including atrial fibrillation or evidence of prior myocardial infarction
  • corrected through use of Fridericia's formula (QTcF) >450 ms demonstrated by at least two ECGs >30 minutes apart
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome
  • Current treatment with medications that are well known to prolong the QT interval
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Part 1: Cohort 1 - NXT007 Dose Level 1 (Low)

    Drug: NXT007

  • Experimental
    Part 1: Cohort 2 - NXT007 Dose Level 2

    Drug: NXT007

  • Experimental
    Part 1: Cohort 3 - NXT007 Dose Level 3

    Drug: NXT007

  • Experimental
    Part 1: Cohort 4 - NXT007 Dose Level 4

    Drug: NXT007

  • Experimental
    Part 1: Cohort 5 - NXT007 Dose Level 5 (High)

    Drug: NXT007

  • Experimental
    Part 2: Cohort A - NXT007

    Drug: NXT007

Interventions

  • DrugNXT007

    Participants will receive NXT007 administered subcutaneously (SC), 2 loading doses once every two weeks (Q2W) followed by once every 4 weeks (Q4W) maintenance doses based on the schedule.

    Also known as: Zemocimig, RO7589655, RG6512

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Grading Scale

    Time frame: From Baseline until study completion or discontinuation (up to 7.5 years)

  2. Number of Participants with at Least One Clinical Laboratory Test Abnormality for Hematology Parameters

    Time frame: From Baseline until study completion or discontinuation (up to 7.5 years)

  3. Number of Participants with at Least One Clinical Laboratory Test Abnormality for Blood Chemistry Parameters

    Time frame: From Baseline until study completion or discontinuation (up to 7.5 years)

  4. Number of Participants with at Least One Vital Sign Abnormality

    The vital signs that will be assessed are body temperature, pulse rate, respiratory rate, and systolic and diastolic blood pressure.

    Time frame: From Baseline until study completion or discontinuation (up to 7.5 years)

  5. Number of Participants with at Least One Abnormality on Electrocardiogram (ECG) Recordings

    The ECG parameters that will be assessed are heart rate, PR interval, QRS interval, QT interval, and QTcF inteval.

    Time frame: From Baseline until study completion or discontinuation (up to 7.5 years)

Secondary outcomes

  1. Plasma Concentration of NXT007 at Specified Timepoints

    Time frame: At prespecified timepoints from Week 1 to Week 23, every 28 days from Week 25 until Week 49, and every 12 weeks thereafter until study completion or discontinuation (up to 7.5 years)

  2. Maximum Observed Plasma Concentration (Cmax) of NXT007 After the First Dose

    Time frame: At prespecified timepoints from Day 1 to Day 15

  3. Time to Maximum Observed Plasma Concentration (tmax) of NXT007 After the First Dose

    Time frame: At prespecified timepoints from Day 1 to Day 15

  4. Area Under the Plasma Concentration-Time Curve (AUC) of NXT007 After the First Dose

    Time frame: At prespecified timepoints from Day 1 to Day 15

  5. Number of Participants Testing Positive for Anti-Drug Antibodies Against NXT007 at Baseline and During Treatment with Study Drug

    Time frame: Baseline (predose on Day 1) and from first dose of study drug until study completion or discontinuation (up to 7.5 years)

  6. Number of Participants Testing Positive for Anti-Factor VIII Inhibitors at Baseline and During Treatment with Study Drug

    Time frame: Baseline (predose on Day 1) and from first dose of study drug until study completion or discontinuation (up to 7.5 years)

  7. Model-Based Annualized Bleeding Rate for Treated Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  8. Mean Calculated Annualized Bleeding Rate for Treated Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  9. Median Calculated Annualized Bleeding Rate for Treated Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  10. Model-Based Annualized Bleeding Rate for All Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  11. Mean Calculated Annualized Bleeding Rate for All Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  12. Median Calculated Annualized Bleeding Rate for All Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  13. Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  14. Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  15. Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  16. Model-Based Annualized Bleeding Rate for Treated Joint Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  17. Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

  18. Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds

    Time frame: From first dose of study drug until study completion or discontinuation (up to 7.5 years)

07

Study locations

12 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2033, 122 months after the start.

Of 20 phase 1/2 interventional studies under Hemophilia A, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 94. This study's planned 122 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2023
First posted
Aug 14, 2023
StartActual
Sep 21, 2023
Primary completionEst.
Dec 11, 2033
CompletionEst.
Dec 11, 2033
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05987449
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Sep 21, 2023
Primary completion
Dec 11, 2033 (estimated)
Completion
Dec 11, 2033 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: WP44714 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NXT007

Start the discussion